Clinical trial

Antiproteinuric Effects of Liraglutide Treatment

NCT02545738

Study summary

ClinicalTrials.gov

Antiproteinuric Effects of Liraglutide Treatment

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Liraglutide Normalized identity: liraglutide View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention placebo Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2015-04-01

PhasePHASE4

Conditions

Diabetic Kidney Diseaseverified · MONDO: diabetic kidney disease

Interventions

LiraglutideDRUG · verified · RxNorm: liraglutide

placeboDRUG

Sponsors & collaborators

Steno Diabetes Center Copenhagenlead sponsor

Novo Nordisk A/Scollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02545738 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.